Aung San Suu Kyi Moved to House Arrest Amid Myanmar Political Crisis 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
Cisco Restructures for AI Growth After Record Q3 Revenue 
Dulles Airport Rebuild Plan Could Transform Washington’s Main International Gateway 
US Trade Court Blocks Trump’s 10% Global Tariffs 
U.S. Army Soldier Charged in $400K Insider Betting Scheme on Maduro Capture 
Japan’s Top Banks to Gain Access to Anthropic’s Claude Mythos AI Model 
Bolsonaro Discharged After Shoulder Surgery Amid Ongoing Legal Troubles 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
DOJ Ends Probe Into Fed Chair Jerome Powell, Boosting Kevin Warsh Confirmation Prospects 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Trump-Xi Summit Sparks Renewed Hope for Americans Detained in China 
Coles “Down Down” Ruling Sparks Fresh Scrutiny of Australian Supermarket Pricing 
Trump and IRS in Settlement Talks Over $10 Billion Tax Return Leak Lawsuit 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Pfizer (NYSE:PFE) has agreed to pay $59.7 million to resolve allegations that Biohaven Pharmaceuticals, acquired by Pfizer in October 2022, defrauded Medicare and other healthcare programs by offering kickbacks to doctors prescribing its migraine drug, Nurtec ODT. The settlement was announced by the U.S. Department of Justice.
The charges stem from Biohaven's activities between March 2020 and September 2022, where the company allegedly violated the False Claims Act by incentivizing doctors with speaker honoraria and luxury meals. Some events were reportedly attended multiple times by the same doctors or by their family members and colleagues with no educational benefit.
Pfizer ended Biohaven's speaker programs shortly after its $11.5 billion acquisition. The company emphasized its focus on patient needs, stating it was "pleased to put this legacy matter behind us." Pfizer did not admit any wrongdoing in the settlement.
The case originated from a whistleblower lawsuit filed in 2021 by Patricia Frattasio, a former Biohaven sales specialist. Frattasio will receive $8.4 million of the settlement under the False Claims Act, which allows whistleblowers to sue on behalf of the government and share in recoveries.
From the settlement, $41.8 million will be allocated to the federal government, while $9.5 million will go to state Medicaid programs. U.S. Attorney Trini Ross reiterated the importance of ensuring that prescriptions are based on medical judgment, not financial incentives.
This resolution underscores the Justice Department’s commitment to tackling healthcare fraud and safeguarding the integrity of Medicare and Medicaid programs.
